Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Y-mAbs Therapeutics, Inc. (YMAB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Quarterly results|
Docs:
|
"Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets September 30, December 31, 2022 2021 ASSETS CURRENT ASSETS Cash and cash equivalents $ 114,526 $ 181,564 Accounts receivable, net 9,251 7,712 Inventories 6,242 5,512 Other current assets 3,225 7,473 Total current assets 133,244 202,261 Property and equipment, net 1,372 1,847 Operating lease right-of-use assets 2,169 3,842 Intangible assets, net 1,530 1,663 Other assets 5,600 3,170 TOTAL ASSETS $ 143,915 $ 212,783 LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Accounts payable $ 13,723 $ 13,552 Accrued liabilities 17,092 12,540 Operating lease liabilities, current portion 1,200 1,783 Total current liabilities 32,015 27,875 Accrued milestone payments 2,250 2,100 Operating lease liabilities, long-term portion 1,019 1,851 Other liabiliti..." |
|
| 08/08/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results|
Docs:
|
"Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets December 31, December 31, 2021 2020 ASSETS CURRENT ASSETS Cash and cash equivalents $ 181,564 $ 114,634 Accounts receivable, net 7,712 — Inventories 5,512 — Other current assets 7,473 7,729 Total current assets 202,261 122,363 Property and equipment, net 1,847 1,825 Operating lease right-of-use assets 3,842 4,569 Intangible assets, net 1,663 — Other assets 3,170 3,290 TOTAL ASSETS $ 212,783 $ 132,047 LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Accounts payable $ 13,552 $ 9,372 Accrued liabilities 12,540 8,197 Operating lease liabilities, current portion 1,783 1,966 Total current liabilities 27,875 19,535 Accrued milestone and royalty payments 2,100 2,695 Operating lease liabilities, long-term portion 1,851 2,013 Other liabilities ..." |
|
| 11/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results|
Docs:
|
"Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets June 30, December 31, 2021 2020 ASSETS CURRENT ASSETS Cash and cash equivalents $ 233,587 $ 114,634 Accounts receivable, net 8,517 — Inventories 3,820 — Other current assets 3,445 7,729 Total current assets 249,369 122,363 Property and equipment, net 1,919 1,825 Operating lease right-of-use assets 3,398 4,569 Other assets 4,793 3,290 TOTAL ASSETS $ 259,479 $ 132,047 LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Accounts payable $ 6,803 $ 9,372 Accrued liabilities 12,169 8,197 Operating lease liabilities, current portion 2,014 1,966 Total current liabilities 20,986 19,535 Accrued milestone and royalty payments 2,250 2,695 Operating lease liabilities, long-term portion 988 2,013 Other liabilities 939 1,968 TOTAL LIABILITIES 25,163 26,..." |
|
| 05/06/2021 |
8-K
| Quarterly results |
| 02/25/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results|
Docs:
|
"Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets September 30, December 31, 2020 2019 ASSETS CURRENT ASSETS Cash and cash equivalents $ 131,267 $ 207,136 Other current assets 1,942 4,819 Total current assets 133,209 211,955 Property and equipment, net 1,888 2,052 Operating lease right-of-use assets 5,123 1,989 Other assets 2,975 370 TOTAL ASSETS $ 143,195 $ 216,366 LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Accounts payable $ 10,320 $ 8,520 Accrued liabilities 7,570 4,550 Operating lease liabilities, current portion 1,887 516 Total current liabilities 19,777 13,586 Accrued milestone and royalty payments 2,466 1,921 Operating lease liabilities, long-term portion 2,517 1,714 Other liabilities 1,923 242 TOTAL LIABILITIES 26,683 17,463 STOCKHOLDERS’ EQUITY Preferred stock, $0.0001 ..." |
|
| 08/06/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 03/12/2020 |
8-K
| Quarterly results |
| 11/13/2019 |
8-K
| Quarterly results |
| 08/14/2019 |
8-K
| Quarterly results |
| 05/10/2019 |
8-K
| Quarterly results|
Docs:
|
"Y-mAbs Announces First Quarter 2019 Financial Results and Recent Corporate Developments , May 10, 2019 — Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter of 2019. “We believe Y-mAbs is adapting very well to its new role as a public company, and we are very pleased with our first quarter financial results, especially seen in conjunction with our clinical progress moving closer to our expected target of being able to file BLAs for both of our two lead pediatric drug candidates, naxitamab and omburtamab in 2019. These are exciting times for Y-mAbs,” stated Thomas Gad, Founder, President and ..." |
|
| 03/22/2019 |
8-K
| Quarterly results|
Docs:
|
"Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights , March 22, 2019 — Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for 2018. “We are very pleased to report our first full year financials after Y-mAbs' successful IPO in September, which we believe has put us in a strong financial position to continue the important work on our two lead pediatric compounds, naxitamab and omburtamab. We plan to file BLAs for both of these compounds by the end of 2019.” stated Thomas Gad, Founder, President and Head of Business Development and Strategy. Dr. Moller, Chief Executive Officer continued, “W..." |
|
| 11/13/2018 |
8-K
| Quarterly results|
Docs:
|
"Y-mAbs Announces Third Quarter 2018 Financial Results and Recent Corporate Developments , November 13, 2018 — Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2018. “We are very pleased to report our first quarterly financials after Y-mAbs' successful IPO in September, which have put us in a strong financial position to continue the important work on our two lead pediatric compounds, naxitamab and omburtamab. We plan to file BLAs for both of these compounds next year.” stated Thomas Gad, Founder, President and Head of Business Development and Strategy. Dr. Moller, Chief Executive Offic..." |
|
|
|